McKesson (MCK)
(Delayed Data from NYSE)
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$485.42 USD
+3.15 (0.65%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $485.43 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Here's Why You Should Hold on to Thermo Fisher (TMO) for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher (TMO) on strength in end markets and raised 2021 guidance.
Making Sense of the Q3 Earnings Picture and Beyond
by Sheraz Mian
Recent updates on the revisions trends have been somewhat disconcerting, as you can see in the chart below that tracks the evolution of Q3 earnings growth expectations...
McKesson (MCK) Up 3.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
McKesson (MCK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2022 results benefit from strong performance across all segments.
McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 35.94% and 5.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for McKesson (MCK) This Earnings Season?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Products' Aug 4 Earnings Roster: MCK, ABC & More
by Trina Mukherjee
The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
McKesson (MCK) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
US States Get $26B Settlement Deal in Opioid Abuse Litigation
by Indrajit Bandyopadhyay
Attorney generals of several states reach settlement deal with J&J (JNJ) and three drug distributors - MCK, CAH and ABC - related to thousands of opioid abuse litigations. Non-participating states may join the deal soon.
McKesson (MCK) Soars 3.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
McKesson (MCK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
McKesson (MCK) Enters Deal to Divest Some European Businesses
by Zacks Equity Research
McKesson (MCK) to sell off some of its European ventures to streamline its business and prioritize investments in areas where it has better expertise.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Should Value Investors Buy McKesson (MCK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Xtrackers Russell US Multifactor ETF (DEUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEUS
Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEO
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.
Should Xtrackers Russell US Multifactor ETF (DEUS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEUS
Strength Seen in McKesson (MCK): Can Its 6.8% Jump Turn into More Strength?
by Zacks Equity Research
McKesson (MCK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.
McKesson (MCK) Q4 Earnings Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 0.60% and -2.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy McKesson (MCK) Ahead of Earnings?
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.